title: Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma: the case for aggressive management.
abstract: OBJECTIVE
  To evaluate the role of allogeneic bone marrow transplantation (BMT) in recurrent low-grade lymphoma.
  
  
  METHODS
  Between 1989 and 1994, 10 patients with chemotherapy-refractory and recurrent low-grade lymphoma were treated with myeloablative therapy and allogeneic BMT. All patients had poor prognostic features and had been extensively pretreated.
  
  
  RESULTS
  Eight patients achieved a complete remission and none have relapsed at a median follow-up time of 816 days (range, 346 to 1,865). Two patients died of early complications. The actuarial survival and failure-free survival rates are both 80% +/- 12.6%. For surviving patients, the duration of the current remission exceeds that of any previous remission achieved.
  
  
  CONCLUSIONS
  These results compare favorably with those for autologous BMT. Allogeneic BMT offers considerable promise for the treatment of patients with poor-prognosis low-grade lymphoma. Its role should be further defined in prospective studies.
authors.affiliation: Department of Hematology, University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.
authors.forename: K W
authors.initials: KW
authors.lastname: van Besien
authors.forename: I F
authors.initials: IF
authors.lastname: Khouri
authors.forename: S A
authors.initials: SA
authors.lastname: Giralt
authors.forename: P
authors.initials: P
authors.lastname: McCarthy
authors.forename: R
authors.initials: R
authors.lastname: Mehra
authors.forename: B S
authors.initials: BS
authors.lastname: Andersson
authors.forename: D
authors.initials: D
authors.lastname: Przepiorka
authors.forename: J L
authors.initials: JL
authors.lastname: Gajewski
authors.forename: N
authors.initials: N
authors.lastname: Bellare
authors.forename: R
authors.initials: R
authors.lastname: Nath
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation; D002066:Busulfan / Q000008:administration & dosage; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D017567:Karnofsky Performance Status; D008228:Lymphoma, Non-Hodgkin / Q000401:mortality / Q000628:therapy*; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D017713:Platelet Transfusion; D012008:Recurrence; D012074:Remission Induction; D016019:Survival Analysis; D013852:Thiotepa / Q000008:administration & dosage; D014184:Transplantation, Homologous; D014916:Whole-Body Irradiation
chemical_list: D005047:Etoposide; D003520:Cyclophosphamide; D013852:Thiotepa; D002066:Busulfan; D002945:Cisplatin; D008727:Methotrexate